Plaque Psoriasis Uncovers Its Alternative Treatments

Alternative treatments to injectable like creams and tablets may soon be available for conditions like plaque psoriasis.

Alternative treatments to injectable — creams and tablets may soon be available for conditions like plaque psoriasis (PsO) as per GlobalData, a leading data and analytics company.

Plaque psoriasis is an incurable condition characterized by painful, red and inflamed patches on the skin. For more than 20 years, the mainstay treatments for PsO were limited to only injectable.

New Plaque Psoriasis Treatment
Plaque Psoriasis characterized by itchy and painful skin disease can be treated better using a breakthrough drug discovered during recent clinical trials than the present medications.

‘Alternative treatments to injectable like creams and tablets may soon be available for conditions like plaque psoriasis.’

However, PsO research and development (R&D) have a made a significant progress with greater levels of innovation (topical creams and tablets) in the pipeline for PsO.

Newer Treatment for PsO

“There will always be a place for injectable biologics in the PsO treatment toolbox, especially in severe patients. However, the recent and future releases of biosimilars will sap the profits of anyone with an expired patent, and essentially open the floodgates of innovation in the field,” says Tiffany Chan, an Immunology Analyst at GlobalData.

Novartis Launches Scapho Drug for the Treatment of Psoriasis
The generic name of Scapho is secukinumab, which is an injectable medicine and the first interleukin-17A (IL-17A) inhibitor to be approved in India.

This paves way for newer opportunity for manufacturers towards the targeted and diverse therapies for PsO patients.

Among the leading group of companies involved in the change are:

Epidemiology Forecast of Plaque Psoriasis in 2030
Plaque psoriasis population to reach over 16.8 million by 2030 in the 7MM influenced by obesity, type 2 diabetes, and smoking.

First group:

Belgium-based UCB
Swedish company Affibody
German’s Merck

Second group:

US-based Bristol-Myers Squibb
India’s Dr. Reddy’s Laboratory
Israel’s Can-Fite Biopharma

Third group:

US-based companies — Arcutis and Dermavant

“The lack of treatments for patients at either extremity of the disease spectrum gives scope for new entrants to significantly grow the market. By attempting to fulfill specific unmet needs, pharmaceutical companies could generate new treatment options for patients that could reduce the need for administration and monitoring by healthcare professionals,” says Chan.

Source-Medindia